Assembly Biosciences Market Cap 2012-2026 | ASMB

Assembly Biosciences market cap history and chart from 2012 to 2026. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Assembly Biosciences market cap as of September 16, 2026 is $0.52B.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.519B $0.072B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $44.899B 17.67
BridgeBio Pharma (BBIO) United States $13.352B 0.00
Dr Reddy's Laboratories (RDY) India $9.749B 24.85
Aspen Pharmacare (APNHY) South Africa $4.248B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.409B 20.18
Bausch Health Cos (BHC) Canada $2.129B 1.33
Personalis (PSNL) United States $1.687B 0.00
Taysha Gene Therapies (TSHA) United States $1.652B 0.00
Amphastar Pharmaceuticals (AMPH) United States $1.019B 9.58
Sol-Gel Technologies (SLGL) Israel $0.178B 0.00
Metagenomi Therapeutics (MGX) United States $0.043B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00